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Breast cancer-specific mortality is static in older women despite having fallen in younger age groups, possibly due to lack of screening
and differences in treatment. This study compared stage and treatment between two cohorts of postmenopausal women (55–69 vs
470 years) in a single cancer network over 6 months. A total of 378 patients were studied (470: N¼167, 55–69 years: N¼210).
Older women presented with more advanced disease (470: metastatic/locally advanced 12%, 55–69 years: 3%, Po0.01). Those
with operable cancer had a worse prognosis (Nottingham Prognostic Index (NPI) 470: median NPI 4.4, 55–69 years: 4.25, Po0.03).
These stage differences were partially explained by higher screening rates in the younger cohort. Primary endocrine therapy was used
in 42% of older patients compared with 3% in the younger group (Po0.001). Older women with cancers suitable for breast
conservation were more likely to choose mastectomy (470: 57.5% mastectomy rate vs 55–69 years: 20.6%, Po0.01). Nodal
surgery was less frequent in older patients (470: 6.7% no nodal surgery, 55–69 years: 0.5%, Po0.01) and was more likely to be
inadequate (470: 10.7% o4 nodes excised, 55–69 years: 3.4%, Po0.02). In summary, older women presented with more advanced
breast cancer, than younger postmenopausal women and were treated less comprehensively.
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Breast cancer incidence increases with age and, as the UK
population ages, is becoming more common (Quinn et al, 2001).
Although the overall mortality rate for breast cancer is declining,
on an age-specific basis, the mortality rate in the elderly has been
static (Quinn et al, 2001). This may reflect a number of factors
such as the lack of screening in older woman resulting in a more
advanced stage at presentation (Tabar et al, 2003), or differences in
treatment with age, which have previously been demonstrated in
both the UK and USA (Golledge et al, 2000; Yancik et al, 2001).
STAGE DIFFERENCES AT PRESENTATION
Breast screening in the UK is presently available to all women
between 50 and 65 years by automatic recall and on demand for
women over this age. However, uptake rates for voluntary breast
screening in older women are low (with only 10% of all screen
detected cancer arising in the over 65 years age group in the UK
(NHS Breast Screening Program Audit, 2003). Screening reduces
the stage at presentation of breast cancer in the under 70 years age
group and improves breast cancer survival (Tabar et al, 2003). In
the over-70 years age group the evidence that screening reduces
mortality is limited, but there may be some benefit (Van Dijck et al,
1997). The benefit may be less in older women because although
the incidence of breast cancer is greater, breast cancer-specific
mortality is lower due to increased nonbreast cancer deaths. For
example, 73% of deaths in breast cancer patients in the 50–54 year
age group are due to breast cancer compared to only 29% of deaths
in women over 85 years (Diab et al, 2000). This dilutes any survival
benefit from breast cancer treatment so differences may be difficult
to detect. Stage at presentation also differs in older women because
they are less likely to self-examine (Siahpush and Singh, 2002) and
therefore the size of the primary cancer is greater at diagnosis
(Diab et al, 2000; Golledge et al, 2000), and the incidence of
advanced disease may be greater (Yancik et al, 1989).
TREATMENT DIFFERENCES
Ideally, the treatment for breast cancer should be evidence based
and tailored to the patient’s wishes and physical limitations. Older
patients have a greater incidence of comorbidity than younger
patients (Yancik et al, 2001) and therefore treatment options may
differ.
Primary endocrine therapy
There is greater utilisation of primary endocrine therapy, PET (i.e.
tamoxifen as sole treatment) in older women. However, the five
randomised controlled trials which have compared tamoxifen vs
surgery have demonstrated better local control with surgery than
with tamoxifen (Robertson et al, 1992; Gazet et al, 1994; Bates et al,
2001; Fentiman et al, 2003; Mustacchi et al, 2003). However, only
one of these studies showed a reduction in survival with tamoxifen
after 12 years of follow-up (Bates et al, 2001). Therefore, studies
indicate that primary endocrine therapy is only justified in patients
with ER-positive tumours and significant comorbidity preventing
surgical treatment. Despite this evidence, use of primary endocrine
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ltherapy is still widespread in the UK (Monypenny, 2003) with
almost 20% of patients aged 65–79 years receiving PET and almost
60% of women over 80 years. However it should be noted that the
patients recruited into the above randomised trials were all fit for
surgery. In a population study, there will be some women with
severe comorbidity, where surgery and anaesthesia may be
associated with significant risks of morbidity and mortality and
life expectancy would be limited. In such patients, PET may be the
appropriate treatment.
Adjuvant chemotherapy
There is limited evidence for the role of adjuvant chemotherapy in
the treatment of older women with breast cancer. The Early Breast
Cancer Trialist’s Collaborative Group indicated a similar magni-
tude of response to adjuvant chemotherapy in patients over 70
years compared to those between 60 and 69 years, but this did not
reach significance, probably due to low numbers in this age group
(EBCTCG, 1998). More recent evidence suggests that chemother-
apy for oestrogen receptor-negative cancers in the elderly may
confer a survival advantage (International Breast Cancer Study
Group, 2002). At present, most UK Units do not routinely
prescribe adjuvant chemotherapy for breast cancer in older
women due to this reduced evidence of benefit and increased
toxicity.
Adjuvant radiotherapy
Radiotherapy after breast-conservation surgery reduces the rate of
local recurrence from 35 to 10–12% and may reduce mortality
slightly (EBCTCG, 2000). There is evidence that local recurrence
rates may be lower in older women (Benhaim et al, 2000) and a
randomised trial is evaluating the role of adjuvant radiotherapy in
older patients with good prognosis breast cancer (PRIME Trial,
Kunkler et al, 2001). Despite the lack of evidence from randomised
controlled trials there may be a tendency to omit radiotherapy
after breast-conservation surgery in older patients (Reed and
Morrison, 1989).
There are little data about the use of chest wall radiotherapy
after mastectomy in older women, although in younger women
local recurrence rates are reduced by two-thirds. National Guide-
lines advise its use if there is a high risk of local recurrence (NICE,
2002), such as if there is margin involvement, heavy nodal disease
(44 positive nodes) or a large (T3) tumour.
Type of surgery to the breast
Studies demonstrate wide variation in the proportion of mastec-
tomies performed in older patients. Some studies indicate that
older women are less likely to be treated by mastectomy than by
breast conservation (Diab et al, 2000; Gajdos et al, 2001) others
that they are more likely (Monypenny, 2003) and some that there is
no difference (Grube et al, 2001). Certainly, the most recent UK
data favour mastectomy as the most common choice for older
women (Monypenny, 2003). This may be because older women
present with larger primary cancers (Diab et al, 2000; Golledge
et al, 2000), making breast-conservation inappropriate, or may be
less concerned with body image and choose the more simple
therapeutic option of mastectomy.
Axillary surgery
There is a tendency to perform less-extensive axillary surgery in
older women (Feigelson et al, 1996; Brenin et al, 1999). Sampling
or sentinel node biopsy may provide an alternative to axillary
clearance but a positive sample may necessitate further surgery or
radiotherapy with the potential for greater morbidity. Further-
more, the omission of axillary surgery means that the 35% of
patients who have nodal disease may develop regional disease
progression.
There are therefore many ways in which the treatment of older
patients with breast cancer may differ from that of younger
patients, some justifiable, others less so.
The aim of the current study was to examine both the stage at
diagnosis and primary and adjuvant treatments of two cohorts of
postmenopausal women from a single cancer network in the UK
over a 6-month period. Women over the age of 70 years were
compared with women of 55–69 years. National and local protocol
adherence was assessed for both age groups and reasons for any
variance were examined.
A further aim of this study was to evaluate the proportion of
older patients who would be eligible for recruitment to a trial of
adjuvant chemotherapy based on prognosis and comorbidity.
METHODS
All patients presenting with invasive or noninvasive breast cancer
over a 6-month period in a single UK Regional Cancer Network
(North Trent) were included in this study. The region comprises
the Sheffield Cancer Centre and five associated Cancer Units. Cases
were identified from multidisciplinary team records, which
prospectively record 99% of all breast cancers in the region.
Patients included in the study were aged 55 years or over at the
time of diagnosis. Case notes were examined to obtain data
concerning comorbid conditions, drug history, clinical features of
the primary cancer, type of primary and adjuvant treatment and
stage and histological features of the tumour. The Nottingham
Prognostic Index was recorded for patients who underwent
surgery to both breast and axilla (NPI, a prognostic scoring
system based on the size of primary tumour, grade and nodal
status, Haybittle et al, 1982).
The oestrogen receptor status of the tumour was recorded where
available using the McCarty H score (score between 0 and 300
reflecting the percentage of cells staining for oestrogen receptors
and the intensity of the staining, McCarty et al, 1983). Treatment
related side effects were also recorded.
The Region has guidelines for the management of breast cancer
(based on UK National Guidelines, National Institute for Clinical
Excellence, BASO, 1998; and NICE, 2002) and all treatment choices
were compared with these guidelines to assess compliance with the
guidelines or whether valid reasons for noncompliance were
documented.
Statistical analysis was by w
2 or Mann–Whitney U test.
Statistical significance was accepted at Po0.05.
All data are represented as percentages or median plus range.
RESULTS
A total of 378 patient records were examined between March 2002
and August 2002. Of these, 210 were in the age range 55–69 years,
with a median age of 62 years (range 55–69 years) and 167 were in
the age range 70 years and over, with a median age of 78.9 years
(range 70–98 years). Overall, there were 280 patients with
symptomatic breast cancer and 98 referred from breast screening.
Very few of the over 70 years age group were screen detected, with
seven out of 167 (4.1%) in the older group compared with 91 of 210
(43.3%) in the younger patients.
Diagnostic process
National Guidelines recommend the use of triple assessment for
the diagnosis of breast cancer (combination of clinical examina-
tion, mammography (7 ultrasound) and biopsy (BASO, 1998;
NICE, 2002). Older women were less likely to have full triple
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lassessment and were less likely to undergo either mammography
or biopsy (core/FNA/surgical), (Po0.05, Table 1).
Stage at presentation
Full histopathological staging was available in 111 (66.5%) of the
older age group compared with 199 (94.8%) of the younger age
group (Po0.001). This was because a larger proportion of older
women either did not receive surgery (treatment with PET) or had
omission of axillary surgery.
Advanced cancer
Older women were more likely to present with advanced disease
(both locally advanced, inoperable primary disease or metastatic
disease, Po0.01, Table 2). This difference persisted when screen
detected cancers were excluded and symptomatic patients only
were analysed for advanced disease (inoperable and metastatic).
Primary operable breast cancer
There was a significant stage difference in the percentage
presenting with primary operable cancer with good, excellent or
moderate prognosis tumours favouring the younger age group and
poor prognosis tumours more frequent in the older age group
(Figure 1). The median Nottingham Prognostic Index (NPI) for the
older age group was 4.4 vs 4.25 in the 55–69 age group (Po0.03).
This difference in NPI disappeared when screen detected cancers
were excluded. Breakdown of NPI into its components (grade,
tumour size, nodal disease), revealed that the difference in NPI was
due to older patients having larger primary cancers (both on
clinical and histopathological evaluation). Older patients also had
higher-grade tumours and more nodal disease, but these
differences were not significant (Table 3).
Ductal carcinoma in situ (DCIS)
There was a significantly greater incidence of DCIS in the younger
age group, with 14 women in the 55–69 age group (7.3%)
compared to three in the over 70 age group (3.4%, Po0.05,
Table 2). Again this difference disappeared when screen-detected
cases were excluded.
Table 1 Summary of percentage compliance with guidelines by age group
Guideline Guideline source
% compliance
55–69 years
% compliance
470 years
Statistical
significance
Triple assessment complete 1,2,3 98.1 81.4 Po0.001
Mammogram performed 1,2,3 98.6 85.6 Po0.001
Biopsy performed, (FNA, core or surgical) 1,2,3 100 97 Po0.02
Surgical treatment should not be withheld on grounds of age alone 1,2 100 97.6 Po0.05
Axillary staging with minimum of four nodes sampled 1,2,3 96.1 83.1 Po0.001
Radiotherapy after breast-conservation therapy 1,2,3 94.7 80 Po0.05
Radiotherapy after mastectomy if indicated
a 39 7 7 0 Po0.01
Adjuvant tamoxifen (ER+ cancer) 1,2,3 97.8 98 NS
Statistical significance tested with w
2.N S¼no significant difference.
aLocal Protocol Indications for chest wall radiotherapy after mastectomy; Tumour 45cm diameter and/or
close/involved deep margin and/or nodal disease. 1¼NICE, 2002, 2¼BASO, 1998, 3¼Local guidelines.
Table 2 Stage at presentation of breast cancer
Stage at presentation All patients (%) Symptomatic patients (%)
Age group (years) 470 55–69 470 55-69
Total number of patients 167 (100) 210 (100) 160 (100) 119 (100)
DCIS 3 (1.8)
a 14 (6.6) 3 (1.9) 3 (2.5)
Primary operable breast cancer (stages I and II) 144 (86.2) 189 (90) 144 (90) 112 (94.1)
Locally advanced, Stage III 9 (5.4)
a 3 (1.4) 9 (5.6) 2 (1.7)
Metastatic, Stage IV 11 (6.6)
a 4 (1.9) 11 (6.9)
a 2 (1.7)
It was not possible to discriminate stage I and II adequately for this study due to the high percentage of patients in the older age group who received no surgery or inadequate
axillary surgery.
aDenotes statistically significant difference from value in younger age group, Po0.05.
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Figure 1 Prognostic group according to age in patients treated surgically
for breast cancer. Graph shows percentage of patients in both age groups
who were treated with surgery, including some form of axillary surgery for
those with invasive carcinoma. These data exclude those in whom axillary
staging was omitted or inadequate. DCIS: ductal carcinoma in situ.
Nottingham Prognostic Index is the sum of the grade (1–3), the nodal
status (no nodal disease¼1, up to three nodes involved¼2, four or more
nodes involved¼3) and the size of the tumour in cm divided by 5). The
higher the score, the worse the prognosis.
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lOestrogen receptor status
Women in the older age group had tumours with significantly
greater oestrogen receptor staining (Po0.007). The median H
score in the older age group was 204 (range 0–270), compared to
180 (range 0–276) in the 55–69 year age group.
Treatment
Treatment variance between hospitals Comparison of treatment
practices between units was performed and showed no significant
differences with any of the Units, although patient numbers were
small in some subgroups (data not shown).
Primary endocrine therapy There are no guidelines relating to the
use of PET as sole treatment for breast cancer (BASO, 1998; or
NICE, 2002). Local control is significantly worse, but there is little
evidence of mortality difference. Most authors advise its use only
for women with ER-positive tumours who are unfit for surgery
(Fentiman et al, 2003). Significantly more patients were treated
with primary endocrine therapy (70 out of 167, 41.9%), in the over
70 age group compared to the younger age group (six out of 210,
2.8%, Po0.00). The majority of patients had a clear indication for
PET in both age groups with most having either metastatic or
inoperable disease or significant comorbidity likely to reduce life
expectancy (Table 4). In both age groups, there were patients who
opted for PET having been offered a choice of PET or surgery,
although the extent of counselling was rarely documented. In 12
out of the 17 older patients who chose PET, significant comorbid
conditions were present. Five patients were otherwise fit and well
and in only one patient was no reason for PET documented.
Surgery
Complications There were no deaths related to breast surgery in
either age group. There were 16 out of 194 (8.2%) wound-related
complications (haematomas and infections) in the 55–69 years age
group vs nine out of 91 (9.8%) in the older age group. Seroma rates
were also similar between the age groups (55–69 years: n¼37,
19%, 70þ: n¼19, 20.8%). Neither difference was statistically
significant. More serious complications were rare in either group.
In the older age group there were two systemic complications, one
case of heart failure and one of confusion. In the younger age
group one patient developed angina.
Surgery to the breast: mastectomy vs breast-conservation therapy
Factors which contraindicate breast-conservation therapy, such as
large tumour size relative to breast size, centrally located tumours,
multifocality or contraindication to postoperative radiotherapy
were identified from the case notes. Using these criteria the
number of cases where breast-conservation surgery was an option
was compared with the number receiving this treatment option. In
the over 70 age group, of the 91 patients who underwent surgery,
40 were suitable for breast conservation. Of these, 23 (57.5%)
elected to have a mastectomy as their first surgical procedure. In
the 55–69 age group, of the 194 patients who underwent surgery,
137 were suitable for breast conservation. Of these, 40 elected to
have mastectomy as their first surgical procedure (20.6%, Po0.01,
Figure 2). Therefore, older women were more likely to undergo
mastectomy, both for reasons relating to the cancer and also due to
patient preference.
Surgery to the axilla UK National Guidelines recommend an
axillary staging procedure during surgery for breast cancer (BASO,
1998). Currently this involves axillary clearance or sampling of at
least four nodes. Sentinel node biopsy is not currently the standard
of care in the UK.
Of the 91 women in the over 70 age group who underwent
surgery, two had no axillary surgery because they had DCIS only.
Of those with invasive disease undergoing surgery (n¼89), six
(6.7%), had no axillary surgery (Po0.01 compared with 55–69 age
group), 22 (24.7%) had axillary node sampling and 60 (67.4%) had
axillary clearance.
In the younger age group, 194 patients had surgery, 14 had no
axillary surgery because they had DCIS only. Of those with invasive
disease, one patient had no axillary surgery (0.5%), 47 (26%) had
axillary sampling and 131 (72.7%) had axillary clearance.
Of those who had some form of axillary staging 9 (10.7%) had
fewer than four nodes assessed in the older age group compared
with six (3.37%) of the younger age group (Po0.02).
Chemotherapy Reduced chemotherapy tolerance and lack of age-
specific evidence of benefit in older women mean that at present
adjuvant chemotherapy for patients over the age of 70 years is not
standard practice in the UK. However, there are no age-specific
exclusion criteria in National Guidelines (BASO, 1998; NICE,
Table 3 Characteristics of primary cancer according to age group
Age 55–69 years Age 470 years
No. evaluable Median + range No. evaluable Median + range
Size of primary cancer (clinical assessment) 151 18mm (0–200mm) 129 26mm
a (0–90mm)
Size of primary cancer (histological assessment 96 17.3mm (1–134mm) 102 23mm
a (4–100mm)
No. evaluable Number of patients (%) No. evaluable Number of patients (%)
Grade 1 180 33 (18.3) 89 14 (15.7) ns
Grade 2 180 75 (41.7) 89 33 (37.1) ns
Grade 3 180 69 (38.3) 89 41 (46.1) ns
Nodes negative 181 124 (68.5) 82 50 (61.7) ns
Nodes positive 181 57 (31.5) 82 31 (38.3) ns
aDenotes statistically significant difference between older and younger age groups, Po0.002. ns: no significant difference.
Table 4 Primary endocrine therapy
Treatment variable 55–69 years 470 years
Total number of patients 210 167
Number treated with Primary Endocrine Therapy 6 (2.8%) 70 (40.3%)
Metastatic or LAPC 3 16
Primary operable breast cancer treated with PET 6 54
Reason for PET
Patient choice 1 17
Unfit for surgery 2 21
Extreme old age 0 4
Dementia 0 5
No reason documented 0 0
Breast cancer treatment in the elderly
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l2002). This study found that 69 out of 210 patients in the younger
age group received chemotherapy, compared with one out of 167
of the older age group (Po0.001).
Adjuvant radiotherapy Radiotherapy to the breast should be
utilised as part of breast-conservation therapy (BASO, 1998; NICE,
2002). Radiotherapy to the chest wall should be administered after
mastectomy in those cases where the risk of local recurrence is
high (BASO, 1998). As in other published reports (Golledge et al,
2000; Diab et al, 2000; Gajdos et al, 2001), older patients were less
likely to receive adjuvant radiotherapy following breast-conserva-
tion surgery (Po0.05). Of those older women eligible for
radiotherapy, 12 out of 15 (80%) received it and those that did
not were over 85 years of age. Of the younger women, five out of 94
(5.3%) did not receive adjuvant radiotherapy for invasive cancer
following WLE. These five patients all had good (n¼1) or excellent
(n¼4) prognosis tumours and declined radiotherapy after
discussion (Table 4).
Chest wall radiotherapy was given to 20 women over 70 and 30
women age 55–69 years (NS, P40.05), although more women who
fulfilled the criteria for chest wall radiotherapy (nodal involve-
ment, T3 tumour or a close or positive posterior margin) did not
receive it in the older than younger age group (Table 1, Po0.01).
Radiotherapy doses were the same regardless of age, for both
radiotherapy to the breast and chest wall. Radiotherapy response
was categorised as none, mild (mild erythema, itching), moderate
(moderate erythema, oedema) or severe (severe erythema, moist
skin desquamation, pain, significant oedema). There was no
significant difference in the incidence or severity of complications
with age (data not shown).
Adjuvant tamoxifen after surgery Adjuvant tamoxifen for 5 years
after surgery is advised for all women with ER-positive tumours
(NICE, 2002). Of 137 eligible younger women, 134 received
tamoxifen (97.8%) compared with 63 out of 64 (98.4%) eligible
older women (NS, Table 1).
DISCUSSION
Tumour stage
This study has demonstrated that stage at presentation of breast
cancer is more advanced in older women and that this difference
may be largely due to lack of mammographic screening. As has
been shown in previous studies, the size of the primary tumour
was greater in older women (Diab et al, 2000; Golledge et al, 2000),
and there were trends for worse grade and nodal status. DCIS was
more common in younger patients when both symptomatic and
screening cases were analysed together, but this difference
disappeared when symptomatic cases only were analysed.
Older women were more likely to present with locally advanced
and metastatic disease, as has previously been shown (Yancik et al,
1989). This excess of advanced disease in the older age group
persists even when symptomatic patients only were examined. This
may reflect reduced breast awareness among older women, who
are less likely to self-examine (Siahpush and Singh, 2002), and may
therefore present with more advanced disease (Hill et al, 1988).
Treatment
This study has identified a number of areas where treatment fails
to comply with guidelines in older women. Some of these
treatment differences were justified, for example, the omission of
chemotherapy, which is nonproven as an adjuvant treatment in the
elderly (EBCTCG, 1998). However, there is recent evidence that
chemotherapy may be of benefit in older women with high-risk
cancers which are ER negative (International Breast Cancer Study
Group, 2002). A multicentre European study of adjuvant
chemotherapy in older patients with poor prognosis breast cancer
has been proposed (ACTION, Adjuvant Cytotoxic ChemoTherapy
In Older WomeN. If the present cohort of older women is
considered, according to stage and fitness, what percentage would
be potential candidates for chemotherapy? The proposed trial may
consider patients for adjuvant chemotherapy if they have an
NPI44.4, regardless of ER status. Of the 91 older patients who had
surgery, 43 had an NPI of 44.4. Of these patients, five had no
comorbidity, 16 had mild comorbidity (e.g. hypertension), four
had no documentation relating to comorbidity and the remaining
19 had serious comorbid disease likely to contraindicate che-
motherapy (e.g. angina, cardiac failure). Therefore of the total 167
patients, 21 would be potential candidates for adjuvant che-
motherapy (12.6%). If we presume that there will be 35 000 new
breast cancer diagnoses per year in the UK, of which one-third (11
667) will be over 70. If our findings are generalisable approxi-
mately 1500 women across the UK would be potential candidates
for chemotherapy annually if such trials find a survival benefit.
Adjuvant radiotherapy was more likely to be omitted in older
women. In many of the cases identified, a valid reason was given
(e.g. inability to lie flat, previous radiotherapy), although in others,
no reason was noted. While there is evidence that radiotherapy
may be of less benefit in the elderly because of lower recurrence
rates (Benhaim et al, 2000), until such studies as the PRIME trial
report all suitable patients should be offered radiotherapy,
regardless of age.
Primary endocrine therapy is still widely used in older women
despite evidence of poor locoregional control. However, in this
study, in the majority of cases, its use was justified in that patients
were ER positive and had a limited life expectancy or severe
comorbidity. There were a small number of cases where fit and
healthy women were treated with PET who could have undergone
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Figure 2 Type of surgery by age group. Graph showing the number of
patients in each age group who underwent surgery as their primary
treatment. The number of patients suitable for breast-conservation surgery
(BCS) was determined by assessing the size of the primary cancer relative
to breast size, multifocality, position of tumour relative to the nipple and
suitability for adjuvant radiotherapy. The number having mastectomy
includes those unsuitable for breast-conservation therapy and those who
were suitable but chose mastectomy.
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lsurgery. Many of these women were offered a choice and chose
tamoxifen, although it is unclear to what extent this was a truly
informed choice.
In summary, this study has demonstrated that women over 70
years of age present with more advanced stage breast cancer and
that their treatment more frequently falls outside of agreed
National and local guidelines than younger women. This may
explain why National mortality statistics show a decline in breast
cancer-specific mortality in all other age groups, but are un-
changed in the elderly (Quinn et al, 2001), where treatment
strategies have not altered for the past 20 years. These patients
have failed to benefit from the significant advances made in the
treatment of breast cancer.
The reasons for treatment of older women outside of guidelines
are varied. Some are justified by patient comorbidity and reduced
treatment tolerance. In many cases there is insufficient research
evidence to guide decision making in this age group and
extrapolation from data relating to younger women is the only
recourse. This may not always be appropriate because of reduced
life expectancy and the slightly different biological behaviour of
the disease in older women (Diab et al, 2000).
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